Cellosaurus WM164 (CVCL_7928)

Cell line name WM164
Synonyms WM-164; WM 164
Accession CVCL_7928
Resource Identification Initiative To cite this cell line use: WM164 (RRID:CVCL_7928)
Comments Part of: Wistar Institute melanoma cell line collection.
Sequence variation: Heterozygous for BRAF p.Val600Glu (Wistar).
Omics: Deep proteome analysis.
Omics: Transcriptome analysis.
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_6357 (451Lu)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Wistar

Markers:
AmelogeninX
CSF1PO11,12
D13S31711
D16S53913
D18S5112,21
D19S43313
D21S1128,31.2
D2S133819
D3S135818
D5S81811,12
D7S8209,10
D8S117913,14
FGA20
TH019
TPOX8,10
vWA14,15
Web pages http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0
http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-metastatic-melanoma-cell-lines-the-primary-lesi
http://www.rockland-inc.com/Product.aspx?id=50688
Publications

PubMed=2918552; DOI=10.1093/jnci/81.6.440
Iliopoulos D., Ernst C., Steplewski Z., Jambrosic J.A., Rodeck U., Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
J. Natl. Cancer Inst. 81:440-444(1989)

PubMed=2156614
Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A., Baird J., Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.
In vitro properties of human melanoma cells metastatic in nude mice.
Cancer Res. 50:2296-2302(1990)

PubMed=8342600
Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.
Am. J. Pathol. 143:528-537(1993)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

Cross-references
Gene expression databases GEO; GSM186471
GEO; GSM186472
GEO; GSM952584
Polymorphism and mutation databases Cosmic; 888857
Cosmic; 897481
Cosmic; 928684
Cosmic; 1155550
Cosmic; 1187586
Cosmic; 1303065
Proteomic databases PRIDE; PXD004343